Could Intercept Pharmaceuticals Inc Change Direction After Today’s Bullish Options Activity?

 Could Intercept Pharmaceuticals Inc Change Direction After Today's Bullish Options Activity?

In today’s session Intercept Pharmaceuticals Inc (ICPT) registered an unusually high (1,040) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious ICPT increase. With 1,040 contracts traded and 1134 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: ICPT170120C00120000 closed last at: $6.8 or 10.5% down. About 15,613 shares traded hands. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has declined 25.63% since April 14, 2016 and is downtrending. It has underperformed by 30.31% the S&P500.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Ratings Coverage

Out of 16 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 9 rate it a “Buy”, 4 “Sell”, while 3 “Hold”. This means 56% are positive. Intercept Pharmaceuticals has been the topic of 25 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Wedbush on Monday, August 10. Goldman Sachs maintained Intercept Pharmaceuticals Inc (NASDAQ:ICPT) rating on Tuesday, May 31. Goldman Sachs has “Neutral” rating and $128 price target. Vetr upgraded it to “Strong-Buy” rating and $207.80 target price in Tuesday, September 22 report. The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has “Outperform” rating given on Tuesday, April 5 by Wells Fargo. On Wednesday, March 30 the stock rating was initiated by Credit Suisse with “Outperform”. The rating was downgraded by Bank of America to “Underperform” on Wednesday, October 28. On Wednesday, July 6 the stock rating was initiated by Cantor Fitzgerald with “Sell”. The rating was maintained by Oppenheimer with “Outperform” on Wednesday, November 18. The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) earned “Outperform” rating by BMO Capital Markets on Thursday, April 7. Cowen & Co maintained Intercept Pharmaceuticals Inc (NASDAQ:ICPT) rating on Tuesday, May 31. Cowen & Co has “Outperform” rating and $215 price target.

According to Zacks Investment Research, “Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company’s lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is initially being developed for the second line treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. is headquartered in New York.”

Insitutional Activity: The institutional sentiment increased to 1.15 in Q2 2016. Its up 0.32, from 0.83 in 2016Q1. The ratio improved, as 32 funds sold all Intercept Pharmaceuticals Inc shares owned while 43 reduced positions. 28 funds bought stakes while 58 increased positions. They now own 20.08 million shares or 7.50% more from 18.68 million shares in 2016Q1.
The California-based Reilly Advsrs Ltd Llc has invested 0% in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Driehaus Capital Mngmt Ltd Llc last reported 3,275 shares in the company. Barclays Public Ltd Liability, a United Kingdom-based fund reported 11,524 shares. Mizuho Secs Usa Incorporated has 0.16% invested in the company for 6,900 shares. Emerald Mutual Fund Advisers Trust holds 0.33% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 41,491 shares. Guggenheim Limited Company accumulated 0.01% or 29,136 shares. Moreover, Emerald Advisers Pa has 0.36% invested in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 52,950 shares. Soros Fund Ltd Liability Corp has 8,100 shares for 0.02% of their US portfolio. Aperio Group Incorporated Lc last reported 0% of its portfolio in the stock. Jpmorgan Chase has 0.03% invested in the company for 829,438 shares. Qvt Limited Partnership last reported 0.72% of its portfolio in the stock. Janney Montgomery Scott Ltd Com holds 0.01% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) for 3,231 shares. Fincl Bank Of New York Mellon Corporation last reported 0% of its portfolio in the stock. Alps, a Colorado-based fund reported 34,551 shares. First Republic Invest Management accumulated 4,585 shares or 0.01% of the stock.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $2.83 billion. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. It currently has negative earnings. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

ICPT Company Profile

Intercept Pharmaceuticals, Inc., incorporated on September 4, 2002, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Firm is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Another recent and important Intercept Pharmaceuticals Inc (NASDAQ:ICPT) news was published by Fool.com which published an article titled: “Why Intercept Pharmaceuticals Inc is Skyrocketing Today” on February 12, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment